Kalvista Pharmaceuticals Inc
KALV13.460USD
+0.250+1.89%
交易中 （美东）报价延迟15分钟
669.80M总市值
亏损市盈率 TTM
关于 Kalvista Pharmaceuticals Inc 公司
KalVista Pharmaceuticals, Inc. 是一家临床阶段制药公司。该公司专注于发现、开发和商业化具有重大未满足需求的疾病的药物疗法。其候选产品是 sebetralstat，一种血浆激肽释放酶抑制剂，正在开发用于遗传性血管性水肿 (HAE)。Sebetralstat 旨在为患有 HAE 的人提供一种药物，可以作为谨慎的口服剂量服用，以便随时治疗 HAE 发作，包括在发作完全发展之前的最早迹象。Sebetralstat 通过针对激肽释放酶-激肽系统 (KKS) 级联起作用，选择性抑制血浆激肽释放酶及其驱动 HAE 发作的不受控制的活动。该公司还在设计一种口服因子 XIIa 抑制剂用于 HAE 预防，使 KalVista 能够解决 HAE 疾病管理的全方位问题。因子 XIIa 抑制剂计划旨在解决其他治疗领域，包括炎症和血栓形成。
公司简介
公司代码KALV
公司名称Kalvista Pharmaceuticals Inc
上市日期Apr 09, 2015
CEOMr. Benjamin L. (Ben) Palleiko
员工数量270
证券类型Ordinary Share
年结日Apr 09
公司地址55 Cambridge Pkwy Ste 901E
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02142-1234
电话18579990075
网址https://www.kalvista.com/
公司代码KALV
上市日期Apr 09, 2015
CEOMr. Benjamin L. (Ben) Palleiko
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
369.60K
+17.30%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
127.94K
+30.30%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
113.03K
+9.80%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Mr. Edward W. Unkart, CPA
Mr. Edward W. Unkart, CPA
Independent Director
Independent Director
--
--
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Stuart
Ms. Nancy Stuart
Independent Director
Independent Director
--
--
Mr. William Fairey
Mr. William Fairey
Independent Director
Independent Director
--
--
Mr. Brian Piekos
Mr. Brian Piekos
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Benjamin L. (Ben) Palleiko
Mr. Benjamin L. (Ben) Palleiko
Chief Executive Officer, Director
Chief Executive Officer, Director
369.60K
+17.30%
Dr. Christopher M. Yea, Ph.D.
Dr. Christopher M. Yea, Ph.D.
Chief Development Officer
Chief Development Officer
127.94K
+30.30%
Dr. Paul K. Audhya, M.D.
Dr. Paul K. Audhya, M.D.
Chief Medical Officer
Chief Medical Officer
113.03K
+9.80%
Ms. Nicole Sweeny
Ms. Nicole Sweeny
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Mr. Edward W. Unkart, CPA
Mr. Edward W. Unkart, CPA
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月3日 周日
更新时间: 8月3日 周日
持股股东
股东类型
持股股东
持股股东
占比
VR Adviser, LLC
13.47%
Tang Capital Management, LLC
9.89%
Suvretta Capital Management, LLC
9.84%
Frazier Life Sciences Management, L.P.
9.78%
Vestal Point Capital, LP
9.51%
Other
47.51%
持股股东
持股股东
占比
VR Adviser, LLC
13.47%
Tang Capital Management, LLC
9.89%
Suvretta Capital Management, LLC
9.84%
Frazier Life Sciences Management, L.P.
9.78%
Vestal Point Capital, LP
9.51%
Other
47.51%
股东类型
持股股东
占比
Hedge Fund
38.74%
Investment Advisor
27.47%
Investment Advisor/Hedge Fund
19.16%
Venture Capital
13.78%
Private Equity
9.78%
Research Firm
3.12%
Individual Investor
1.79%
Pension Fund
0.16%
Bank and Trust
0.08%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
291
60.09M
120.29%
-6.33M
2025Q1
300
56.85M
114.35%
-10.03M
2024Q4
295
57.02M
115.39%
-4.36M
2024Q3
292
50.23M
115.93%
-11.73M
2024Q2
292
49.87M
116.71%
-8.51M
2024Q1
293
49.24M
116.93%
-4.79M
2023Q4
269
38.06M
110.17%
-12.86M
2023Q3
274
38.57M
113.73%
-12.48M
2023Q2
275
36.74M
108.90%
-12.50M
2023Q1
287
35.85M
106.52%
-13.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
VR Adviser, LLC
6.73M
13.53%
+25.00K
+0.37%
Apr 09, 2025
Tang Capital Management, LLC
4.94M
9.94%
+47.95K
+0.98%
Mar 31, 2025
Suvretta Capital Management, LLC
4.91M
9.88%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.89M
9.83%
--
--
Mar 31, 2025
Vestal Point Capital, LP
4.75M
9.56%
-18.71K
-0.39%
Mar 31, 2025
Capital World Investors
3.18M
6.39%
-196.48K
-5.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.7%
+204.53K
+7.78%
Mar 31, 2025
The Vanguard Group, Inc.
2.30M
4.62%
+43.35K
+1.92%
Mar 31, 2025
SilverArc Capital Management, LLC
1.70M
3.42%
+1.09M
+177.53%
Mar 31, 2025
Woodline Partners LP
1.62M
3.25%
+329.07K
+25.54%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.13%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
Fidelity Enhanced Small Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.78%
Invesco NASDAQ Future Gen 200 ETF
占比0.43%
SPDR S&P Biotech ETF
占比0.13%
iShares Micro-Cap ETF
占比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.08%
Fidelity Enhanced Small Cap ETF
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
iShares Biotechnology ETF
占比0.05%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
